SecBot SecBot
PRESS-RELEASE ·Filed Jun 3, 2026

NRXP

NRx Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The dilutive offering (~11% share count increase) is a near-term negative for existing shareholders, though the cash infusion supports the company's clinical pipeline.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.05
T+0 close · Jun 3, 2026 · via day close
Latest settled
−10.62%
T+60 · $3.62
Vs SPY
−13.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $4.05entry
  2. T+1 · 6mo ago 0.00%α −0.40% · $4.05
  3. T+5 · 5mo ago −7.16%α −3.34% · $3.76
  4. T+20 · 5mo ago −4.44%α −3.44% · $3.87
  5. T+60 · 3mo ago −10.62%α −13.12% · $3.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$20.0M ($23.0M if underwriters fully exercise the 30-day option). The offering is dilutive (~11% of pre-offering shares) and proceeds are for working capital and general corporate purposes. The stock closed at $3.50 on June 3, 2026, indicating no premium/discount at pricing.

Key Financial Metrics

Deal Value
$20.0M

Key Facts

  • Pricing of 5,714,286 shares at $3.50 per share
  • Gross proceeds of approximately $20.0 million ($23.0 million if option exercised)
  • Underwriters granted 30-day option to purchase up to 857,142 additional shares
  • Offering expected to close June 4, 2026
  • Proceeds for working capital and general corporate purposes
  • BTIG, LLC is lead bookrunning manager; Lucid Capital Markets is joint bookrunning manager
  • Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)

Financial Impact

~$20M gross proceeds from sale of ~5.7M shares, representing approximately 11% dilution based on pre-offering share count (implied by market cap of $167M and price of $3.50 = ~47.7M shares pre-offering).

dilutioncash

Risk Factors

  • Dilution of ~11% for existing shareholders
  • Proceeds used for working capital, not specific pipeline milestone, signaling potential cash burn concerns
  • Clinical-stage biopharma with no approved products; regulatory setbacks could severely impact valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306024

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026